Viking Therapeutics (LTS:0VQA) OCF Margin %: 0.00% (As of Mar. 2026)


LTS:0VQA Viking Therapeutics Inc LTS:0VQA
36 GF Score
Price $37.72
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics OCF Margin %?

Viking Therapeutics LTS:0VQA -6.86% 36 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 36/100. The stock has 3 warning signs investors should review. Among 955 Biotechnology companies, Viking Therapeutics ranks worse than 104711.94% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Viking Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-113.98 Mil. Viking Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Viking Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Viking Therapeutics's current OCF Yield % is -7.82%.

The historical rank and industry rank for Viking Therapeutics's OCF Margin % or its related term are showing as below:


LTS:0VQA's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Viking Therapeutics OCF Margin % Related Terms

Viking Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics OCF Margin % Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0VQA
36GF Score
Viking Therapeutics Inc LTS:0VQA
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Viking Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-278.685/0
= %

Viking Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-113.976/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Viking Therapeutics (LTS:0VQA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #999999 out of 955 companies in the Biotechnology industry.
Is Viking Therapeutics' OCF Margin % too high?
Viking Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Viking Therapeutics ranks #999999 out of 955 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viking Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' OCF Margin % compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #999999 out of 955 companies for OCF Margin %. This places Viking Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Viking Therapeutics' overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
36GF Score

Get the complete analysis for LTS:0VQA

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.72
Price